US Prevalence
~70,000
Americans living with MG — the most common neuromuscular junction disease. Prevalence rising as population ages and diagnostic recognition improves.[1]
What Is It
Definition, mechanism, and the clinical reality of this diagnosis at end of life. What the hospice team needs to understand on day one.
Refractory MG Rate
10–15%
Of MG patients are refractory — failing ≥2 immunosuppressive agents at adequate doses and duration. This population defines the hospice-relevant cohort.[2]
Crisis Incidence
15–20%
Of MG patients experience at least one myasthenic crisis requiring mechanical ventilation — the defining life-threatening event in MG.[3]
Thymoma Association
~15%
Of MG patients have an associated thymoma. Thymomatous MG is often more severe, more refractory, and the prognosis may be driven by the thymoma as much as the MG.[4]
Myasthenia gravis is an autoimmune disease of the neuromuscular junction — the synapse where nerve signals command muscle contraction. Autoantibodies, most commonly against the acetylcholine receptor (AChR, ~85% of generalized MG) or the muscle-specific tyrosine kinase (MuSK, ~40% of AChR-seronegative MG), block, destroy, or functionally impair the receptor, preventing normal neuromuscular transmission. The clinical consequence is fatigable weakness — weakness that worsens with repeated use and improves with rest. Ocular muscles are affected first in most patients, causing ptosis and diplopia. Bulbar muscles — those controlling speech, swallowing, and breathing — are affected in severe disease, producing the life-threatening triad of dysarthria, dysphagia, and respiratory failure.[1]
End-stage MG in hospice is defined not by inexorable neurological progression — MG is not a degenerative disease — but by the exhaustion of immunomodulatory options, by recurrent crises that no longer fully remit, by the accumulated organ damage from decades of high-dose steroids and immunosuppression, or by the patient's decision that the burden of living in a disease defined by cycles of crisis and partial recovery has exceeded the meaning of continuing. The defining clinical challenge of MG in hospice is the medication danger list: a specific set of commonly prescribed drugs — aminoglycosides, fluoroquinolones, macrolides, beta-blockers, calcium channel blockers, magnesium — that can precipitate myasthenic crisis and death in MG patients. This list must be posted in the home, carried by the patient, and communicated to every provider who may prescribe for this patient.[5]
The second challenge is the extraordinary fluctuation of symptoms. The MG patient who walks and talks at noon may be in respiratory failure by midnight. Good days do not mean recovery. Bad days do not always mean crisis. This fluctuation makes prognostication nearly impossible and makes every family visit a conversation about holding hope and honesty simultaneously.[6]
🧭 Clinical framing
MG in hospice is a disease of two simultaneous dangers. First: the drugs that other providers give this patient can kill them. Aminoglycosides, fluoroquinolones, macrolides, beta-blockers, magnesium — these are commonly prescribed medications that can precipitate myasthenic crisis. The hospice team's first job is making sure no one gives them. Second: the disease fluctuates in ways that defy every prognostic tool the team knows. The patient who had a good week is still end-stage. The patient who is struggling today may improve tomorrow — and then crash. Hold both realities at once. That is what MG hospice care requires.
"Before you look at the patient, look at the medication list. Before you adjust anything, check the danger list. The MG patient who got azithromycin from urgent care last week and ended up intubated — that was preventable. Your first clinical task every visit is making sure nobody has prescribed from the danger list since the last time you were there."
— Waldo, NP · Terminal2
How It's Diagnosed
Diagnostic workup, staging, and what to look for in hospice records. Most patients arrive with an established diagnosis — this section helps you read it.
Serology & Electrodiagnostics
- AChR antibody: Positive in ~85% of generalized MG. The diagnostic cornerstone. Elevated titer in appropriate clinical context confirms diagnosis. Titer does not reliably correlate with disease severity in individual patients.[1]
- Anti-MuSK antibody: Present in ~40% of AChR-seronegative generalized MG. MuSK-MG has distinct features — predominantly bulbar, more refractory to pyridostigmine, less responsive to thymectomy, better response to rituximab.[7]
- Anti-LRP4 antibody: Rare third subtype. Clinical significance still emerging. In hospice, antibody subtype has already been determined — know which type, as it predicts treatment response patterns.[8]
- Repetitive nerve stimulation (RNS): Decrement of ≥10% in compound muscle action potential at 3 Hz is diagnostic. Already performed at diagnosis.[9]
- Single-fiber EMG (SFEMG): Most sensitive test — increased jitter and blocking. Already completed in most hospice patients.[9]
What to Look for in Hospice Records
- Antibody subtype (AChR vs MuSK vs LRP4): Determines treatment response pattern and clinical phenotype. MuSK-MG is more refractory and bulbar-predominant.[7]
- MGFA Classification: Class I = ocular; II = mild generalized; III = moderate generalized; IV = severe generalized; V = intubation. Most hospice patients are Class IV–V at enrollment.[10]
- CT chest / thymoma status: Thymoma present in ~15%. Whether thymectomy was performed. If thymoma is unresectable or recurrent, it drives prognosis independently.[4]
- Baseline FVC and NIF: The most critical monitoring parameters. FVC <1L or NIF worse than −25 cmH₂O indicates impending respiratory crisis. Know the trajectory, not just the single value.[11]
- Crisis history: Number of prior myasthenic crises, intubation duration, recovery pattern. Each successive crisis with less complete recovery defines the refractory trajectory.
- Immunosuppressive treatment history: Which agents tried, why they failed, cumulative steroid burden (years on prednisone, current dose, Cushingoid features, osteoporosis, diabetes).
- IVIG/PLEX history: Frequency, duration of benefit after each course, trend in response — diminishing returns signal disease refractoriness.[12]
💡 For families
💡 Para las familias
Your loved one's MG diagnosis was made using blood tests for specific antibodies and nerve conduction studies. These tests have already been done. At this stage, the focus is not on new testing but on understanding what we already know — what type of MG they have, how their body has responded to treatments, and what patterns of crisis and recovery have shaped their disease. This history tells us how to keep them most comfortable now.
El diagnóstico de miastenia gravis se realizó con análisis de sangre y estudios de conducción nerviosa. Estas pruebas ya se han realizado. Próximamente más información en español.
Causes & Risk Factors
Modifiable and hereditary risk factors. Relevant for family conversations, genetic counseling referrals, and answering "why did this happen?"
Autoimmune Mechanism & Subtypes
- AChR antibody MG (~85%): IgG1/IgG3 antibodies bind, block, and accelerate degradation of acetylcholine receptors. Complement activation destroys the end-plate. Thymus pathology central — myoid cells express AChR; thymoma drives aberrant T-cell maturation.[1]
- MuSK antibody MG (~7%): IgG4 antibodies — no complement activation (different therapeutic implications). Predominantly bulbar and respiratory. More refractory to pyridostigmine. Thymectomy generally not beneficial. Better response to rituximab.[7]
- Seronegative MG (~8%): AChR and MuSK negative. May have low-affinity AChR antibodies or anti-LRP4 antibodies. Clinical features similar to AChR-MG. Diagnosis based on clinical presentation and electrodiagnostics.[8]
- Thymoma-associated MG (~15%): Anterior mediastinal tumor. More severe disease. Thymectomy mandatory for tumor but MG may not improve. Prognosis driven by thymoma staging and histology as much as MG biology.[4]
Triggers of Crisis & Exacerbation
- Infections: The most common crisis trigger. Any systemic infection, especially respiratory. UTI, pneumonia. The MG patient with fever requires urgent MG-specific assessment.[3]
- Medications (DANGER LIST): The most important avoidable trigger — aminoglycosides, fluoroquinolones, macrolides, beta-blockers, calcium channel blockers, magnesium, neuromuscular blocking agents, D-penicillamine, chloroquine/hydroxychloroquine, some statins, iodinated contrast, botulinum toxin.[5]
- Surgery / anesthesia: Neuromuscular blocking agents are absolutely contraindicated. Any surgery requires neuromuscular specialist involvement.[13]
- Emotional stress, heat, pregnancy, thyroid disease: All documented triggers for MG exacerbation. Autoimmune comorbidity (thyroid, RA, SLE) is common — screen at enrollment.[14]
- Tapering immunosuppression too rapidly: Abrupt steroid withdrawal or rapid reduction of maintenance therapy can precipitate crisis.[15]
❤️ For families: "Why did this happen?"
Myasthenia gravis is an autoimmune disease — the body's immune system mistakenly attacks the connections between nerves and muscles. This was not caused by anything your loved one did or did not do. There is no lifestyle factor, no exposure, no missed opportunity that would have prevented this. The immune system made an error, and that error has been the source of everything that followed. The important thing now is not why it happened, but how we manage what it means today — with the best comfort care possible.
⚕ Clinician note: Epidemiology & disparities
MG has a bimodal age distribution — younger peak predominantly women (15–35 years) with hormonal/autoimmune associations, and older peak predominantly men (>50 years) with higher thymoma rates. Overall female predominance ~3:2. Increasing prevalence in elderly reflects improved diagnosis. Documented racial disparities: Black patients with MG present with more severe disease, experience more crises, and have higher mortality — driven by both biological factors (more aggressive phenotype) and systemic barriers to specialist access, IVIG availability, and timely crisis management. The hospice clinician's role is to ensure equitable access to all comfort-focused interventions regardless of socioeconomic status.[16]
Treatments & Procedures
What disease-directed treatments this patient may have received or may still be receiving. Understanding prior therapy helps anticipate complications and interpret the patient's trajectory.
Understanding the treatment history is essential for hospice management of refractory MG. These patients have typically traversed years of escalating immunosuppressive therapy, experienced multiple crises, undergone plasmapheresis and IVIG infusions, and accumulated the cumulative toxicity of chronic high-dose corticosteroids. Each prior treatment informs current symptom management, medication interactions, and the clinical framing of what "refractory" means for this specific patient. The distinction between "failed treatment" and "treatment no longer providing benefit" is critical for the goals-of-care conversation.[15]
Symptomatic & Immunosuppressive Therapy
- Pyridostigmine (Mestinon): Acetylcholinesterase inhibitor — first-line symptomatic treatment. 60 mg q4–6h; max 120 mg q4h before cholinergic crisis risk. Timed 30–45 min before meals for optimal bulbar function. Liquid formulation 60 mg/5 mL for PEG. IV: 1/30th of oral dose (2 mg IV ≈ 60 mg oral). MuSK-MG patients may worsen on pyridostigmine at high doses.[17]
- Prednisone: Cornerstone immunosuppression. Maintenance 10–40 mg daily or alternate-day. Initial high-dose start can cause transient worsening in ~50%. Cumulative burden: Cushingoid features, osteoporosis, diabetes, cataracts, adrenal suppression. Do not stop abruptly — taper gradually.[15]
- Azathioprine: Steroid-sparing; 2–3 mg/kg/day. Requires TPMT testing. Slow onset 12–18 months. Monitor CBC and LFTs.[18]
- Mycophenolate mofetil: 1–3 g/day. Faster onset than azathioprine. Teratogenic. GI side effects. Often tried when azathioprine fails.[18]
- Tacrolimus / Cyclosporine: Calcineurin inhibitors. Renal and metabolic monitoring. Used in refractory cases.[15]
- Rituximab: Anti-CD20 monoclonal antibody. Particularly effective in MuSK-MG — can produce sustained remission. Variable response in AChR-MG. Given IV q6 months.[19]
Rescue Therapies & Procedures
- IVIG (Intravenous Immunoglobulin): 2 g/kg over 2–5 days for acute exacerbation. Maintenance every 4–6 weeks in refractory patients. Mechanism: modulates immune response. Side effects: headache, aseptic meningitis, thromboembolic events, renal toxicity. Insurance access can be barrier.[12]
- Plasmapheresis (PLEX): 5 exchanges over 10–14 days. Removes circulating antibodies. Faster onset than IVIG. Requires central venous access. Used for crisis and pre-operative preparation. Benefit typically lasts 4–6 weeks.[20]
- Eculizumab (Soliris): Complement C5 inhibitor. FDA-approved for refractory AChR-MG. REGAIN trial showed improvement in daily activities. Requires meningococcal vaccination. Extremely expensive (~$500K/year).[21]
- Efgartigimod (Vyvgart): FcRn antagonist — reduces IgG levels. ADAPT trial showed improvement in AChR-MG. IV infusion weekly ×4, then as needed. Newer agent with growing hospice-context experience.[22]
- Thymectomy: Surgical removal of thymus. MGTX trial (Wolfe 2016) showed benefit in non-thymomatous AChR-MG even without visible tumor. Mandatory for thymoma. Already performed in most hospice patients if indicated.[23]
When Therapy Makes Sense
Evidence-based criteria for continuing disease-directed therapy. This is not about giving up or holding on — it's about reading the data correctly.
Refractory MG is not a degenerative disease — it is an autoimmune disease in which immunomodulatory options have been exhausted or the patient has decided the burden of pursuing them exceeds the benefit. The question at hospice enrollment is not whether to treat, but which treatments continue to serve the patient's goals. Many MG-specific therapies are legitimate comfort measures that reduce hospitalization frequency and maintain quality of life.[24]
- 01Pyridostigmine continuation at optimized dose and timing: Pyridostigmine remains appropriate comfort therapy in end-stage MG as long as swallowing function allows oral administration. It is a symptomatic treatment, not an immunosuppressant — it does not change the disease but meaningfully improves function. Dose optimization and timing 30–45 minutes before meals is a primary comfort intervention at enrollment. Liquid formulation via PEG if oral route is compromised.[17]
- 02Stable immunosuppressive therapy continuation: The patient stable on prednisone and azathioprine at tolerated doses may benefit from continuation even in hospice. Stopping immunosuppression risks precipitating crisis requiring aggressive management — the opposite of comfort goals. Reduction should be explicit, gradual, and discussed — never abrupt.[15]
- 03IVIG or PLEX for comfort-directed crisis prevention: If a patient has been receiving regular IVIG or PLEX that prevents crises otherwise requiring hospitalization, continuation as a comfort measure reducing hospitalization frequency is legitimate. The enrollment conversation: is the frequency and burden of infusions still consistent with the patient's goals?[12]
- 04Eculizumab or efgartigimod continuation in stable-responding patients: Same framework as other targeted therapies in hospice. If tolerated and providing measurable benefit, continuation with explicit goals documentation is appropriate.[21]
- 05Respiratory monitoring and early crisis recognition: Serial FVC monitoring (trend >20% decline from baseline or below 1L signals increasing risk). Nocturnal pulse oximetry for hypoventilation. Early action on infections that trigger exacerbation.[11]
- 06Modified texture diet and SLP management for bulbar weakness: Comfort swallowing optimization with pyridostigmine timed to meals. Patient goals explicitly include quality of life and enjoyment of eating as long as safely possible.[25]
When It Doesn't
Knowing when treatment stops helping is not clinical failure. It is the most important clinical skill in this disease.
Refractory MG patients are among the most under-referred to hospice in neuromuscular medicine. The fluctuating course — good days interspersed with crises — makes physicians reluctant to prognosticate and families reluctant to accept that the trajectory is downward. Studies consistently show that palliative care referral in MG occurs later than in degenerative neurological diseases, often only after a prolonged ICU admission for crisis when the patient or family decides against reintubation.[24]
- 01Refractory MG failing ≥2 immunosuppressive agents, IVIG/PLEX no longer providing durable benefit, and no further appropriate therapeutic options: This defines the terminal refractory population. When the disease no longer responds to available treatments and each crisis remits less completely than the last, the trajectory — despite its daily fluctuation — is clear.[2]
- 02Patient decision to decline further IVIG or PLEX: The patient who has been through eight plasmapheresis courses with diminishing returns from each is making a legitimate autonomous decision when they choose to stop. This requires the same process as any other life-sustaining treatment discontinuation: capacity assessment, treatable contributor exploration, full information, and unconditional respect for the stable decision.[26]
- 03Myasthenic crisis with patient advance directive explicitly declining reintubation: The patient who developed MG-specific advance directives during a stable period that decline intubation for crisis has made one of the most clinically and ethically important decisions in neuromuscular medicine. This directive must be honored even in acute crisis. Comfort management: morphine for dyspnea, midazolam for respiratory distress, with full family preparation.[26]
- 04Thymoma driving the trajectory beyond MG management: In unresectable or progressive thymoma-associated MG, the thymoma's oncological trajectory may be the limiting factor. Prognosis from the thymoma must be incorporated into the overall care plan.[4]
- 05Exhaustion from the crisis-remission cycle: The patient who articulates clearly — while cognitively intact, not in acute crisis, having lived with MG for years and able to describe exactly what happens next — that they have decided not to pursue it again, has made a fully autonomous decision that deserves complete clinical support. This is not depression (screen for it, treat it if present). This is a fully informed decision about quality of life.[24]
📋 Clinician note: The ICU-to-comfort transition
The most common pathway to hospice in MG is through the ICU. The patient who has been intubated for a myasthenic crisis, who has failed extubation, or who has been intubated and liberated multiple times, reaches a decision point: pursue tracheostomy and long-term ventilation, or transition to comfort. This conversation must happen with the neuromuscular specialist, the intensivist, and the palliative care team together. The hospice clinician who receives this patient must understand that the decision to extubate to comfort was made in the ICU, not at the bedside — and that the family has already been through an extraordinary ordeal. The first hospice visit is not about introducing hospice philosophy. It is about honoring a decision that was already the hardest one they have ever made.[27]
Out-of-the-Box Approaches
Evidence-graded integrative, interventional, and complementary approaches. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.
MG Medication Danger List as Clinical Safety Intervention
Grade AProtocol: printed danger list posted in home, carried by patient, communicated to all providers
The most important out-of-the-box approach in MG hospice is not a medication or procedure — it is the systematic communication of drugs that precipitate myasthenic crisis. The list: aminoglycosides, fluoroquinolones, macrolides, beta-blockers, calcium channel blockers at high doses, magnesium sulfate, neuromuscular blocking agents, D-penicillamine, chloroquine/hydroxychloroquine, some statins, iodinated contrast, botulinum toxin. MedAlert bracelet or equivalent with "Myasthenia Gravis — see drug list" should be standard. The hospice nurse who catches an azithromycin prescription before it is administered has prevented a crisis hospitalization.[5]
Pyridostigmine Dose Timing Optimization
Grade AProtocol: administer pyridostigmine 30–45 minutes before each meal
Pyridostigmine reaches peak effect ~1 hour after oral dosing. Moving the dose to 30–45 minutes before meals maximizes bulbar function during eating — a comfort intervention that can meaningfully extend safe oral eating and reduce aspiration frequency. This seems simple. It is not. It is rarely implemented correctly. Assess timing at every enrollment and correct if needed. The patient who takes Mestinon with meals is receiving peak benefit after the meal rather than during it.[17]
Comfort-Focused IVIG/PLEX as Hospitalization Prevention
Grade BProtocol: continue maintenance IVIG q4–6 weeks or PLEX per prior schedule if preventing crises
In a refractory MG patient receiving regular IVIG or PLEX that has been preventing crises requiring hospitalization, continuation as a comfort measure is a legitimate and evidence-supported strategy. The goal reframe: this is not disease-directed therapy; it is hospitalization prevention and quality-of-life maintenance. Document this explicitly. Review response after each cycle — discontinue when benefit no longer evident.[12]
MG-Specific Crisis Advance Directive
Grade AProtocol: facilitate detailed crisis advance directive at enrollment during period of stability
The standard DNR/DNI form is insufficient for MG. MG patients need a crisis-specific directive covering: whether to intubate at all, whether to attempt time-limited intubation (e.g., 72 hours for IVIG/PLEX to take effect, then reassess), whether to pursue tracheostomy if extubation fails, and what comfort measures to use if intubation is declined. This document must be created during stability — not during crisis when the patient's voice may be unavailable. It is the most important document in the care plan.[26]
Respiratory Muscle Training in Early Hospice
Grade CProtocol: inspiratory muscle training 15–20 min daily at 30–50% max inspiratory pressure
Limited evidence suggests that respiratory muscle training may maintain respiratory reserve in MG patients who are not in acute crisis. In early hospice enrollment when the patient is relatively stable, this may preserve respiratory function longer. Must be supervised. Discontinue if causing fatigue beyond baseline. Not appropriate in acute or rapidly declining patients.[28]
Structured Fatigue Management Protocol
Grade BProtocol: activity-rest cycling, energy conservation education, scheduled rest periods
MG fatigue is unique — it is fatigable weakness, not the sustained fatigue of other conditions. Activities should be planned for peak pyridostigmine effect. Rest periods before and after exertion are clinical interventions. Occupational therapy for energy conservation. Cool environments (heat worsens MG). Structure the day around the medication schedule.[29]
Natural & Herbal Options
Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to this diagnosis. Patients will use supplements — this section helps you have the right conversation.
"The MG medication danger list is the defining safety framework for ALL supplement recommendations in this diagnosis. Many common herbs and supplements have neuromuscular effects — either worsening neuromuscular transmission or interacting with pyridostigmine's cholinergic mechanism. Before recommending ANY supplement in MG, ask: does this compound affect acetylcholine metabolism, calcium channels, or magnesium levels? If yes — do not recommend without neurologist consultation. The default answer in MG for any supplement with neuromuscular pharmacological activity is: verify first, recommend later."
— Waldo, NP
| Herb / Supplement | Evidence Grade | Typical Dose | Potential Benefit | ⚠ Interactions / Contraindications |
|---|---|---|---|---|
| Vitamin D | Grade C | 2,000–4,000 IU daily | Correction of documented deficiency (target 40–60 ng/mL); associated with reduced autoimmune disease activity generally; safe in MG[30] | No neuromuscular junction activity. No interaction with pyridostigmine. One of the few clearly safe supplements in MG. Monitor 25-OH-D levels. |
| Coenzyme Q10 | Grade D | 100 mg daily | Theoretical mitochondrial support in neuromuscular disease; no MG-specific RCT data; safe profile; many MG patients take it[31] | No documented neuromuscular junction interaction at standard doses. If patient is already using without adverse effect, no reason to discontinue. Mild anticoagulant potential — monitor if on warfarin. |
| Melatonin | Grade C | 1–3 mg at bedtime | Sleep disruption from medication schedule, nocturnal respiratory anxiety, and steroid-induced insomnia; melatonin addresses sleep onset without neuromuscular or respiratory depression risk[32] | No neuromuscular junction effects. No respiratory depression. Theoretical immunomodulatory effects — clinical significance in MG unknown. Low doses preferred. Avoid high-dose formulations. |
| Omega-3 Fatty Acids | Grade C | 1–2 g EPA+DHA daily | Anti-inflammatory properties; general autoimmune disease modulation; may reduce systemic inflammation; evidence in MG specifically is limited[33] | Mild anticoagulant effect — monitor with concurrent anticoagulation. No neuromuscular junction interaction. Fish oil capsules may be difficult to swallow in bulbar MG — liquid formulation available. |
| Probiotics | Grade D | Multi-strain, 10+ billion CFU daily | Gut microbiome modulation; theoretical autoimmune benefit; may address GI side effects of immunosuppressants and antibiotics[34] | No neuromuscular interaction. Generally safe. Avoid in severely immunocompromised patients (risk of translocation). Helpful for azathioprine/mycophenolate GI effects. |
🚫 Avoid in Myasthenia Gravis
- Magnesium supplements (any form including antacids, laxatives): Magnesium blocks neuromuscular transmission at the presynaptic and postsynaptic level. Can precipitate myasthenic crisis. This includes magnesium-containing antacids (Milk of Magnesia, Maalox), laxatives (magnesium citrate), and IV magnesium. Use alternative antacids and laxatives.[35]
- Herbal supplements with acetylcholinesterase-inhibiting properties (e.g., Huperzine A, Galantamine-containing herbs): Additive cholinergic effect with pyridostigmine — risk of cholinergic crisis (excessive secretions, bradycardia, abdominal cramping, diarrhea). Do not combine with pyridostigmine.[5]
- Calcium channel-active supplements (high-dose calcium, certain herbal calcium channel modulators): Calcium channel blockade impairs neuromuscular transmission. Pharmacological mechanism similar to calcium channel blocker medications on the danger list.[5]
- Echinacea and other immune-stimulating herbs: Theoretical risk of autoimmune exacerbation. Immune stimulation is counterproductive in an autoimmune disease being managed with immunosuppression.[36]
- St. John's Wort: CYP3A4 inducer — may reduce levels of tacrolimus, cyclosporine, and other immunosuppressants. Can compromise immunosuppressive therapy effectiveness.[36]
- Kava, Valerian at high doses: CNS depressant effects may compound respiratory depression risk in MG patients with compromised respiratory reserve.[36]
Timeline Guide
A guide, not a prediction. Every patient's trajectory is shaped by histology, molecular profile, treatment response, and comorbidities.
MG is defined by fluctuation rather than linear progression. The trajectory is a series of crises with progressively incomplete remissions rather than steady decline. This makes standard prognostic models inadequate. The timeline below represents a general pattern — any individual patient may deviate significantly. The good day does not mean recovery. The bad day does not always mean crisis. Track the trend across weeks and months, not hours and days.[6]
YRS–
MOS
MOS
Early to Mid MG — Diagnosis & Initial Treatment
- Diagnosis established via serology and electrodiagnostics. Pyridostigmine initiated for symptomatic control. Immunosuppression started — typically prednisone with steroid-sparing agent.
- Possibly thymectomy performed. Ocular or mild generalized disease. Learning the disease, the medication schedule, the triggers to avoid.
- Possibly first myasthenic crisis — ICU admission, intubation, IVIG or PLEX. Achieving partial or full remission with treatment. This phase can last years.
- Palliative care integration is never offered at this stage, but it should be. The advance directive conversation about what the patient would want during a crisis must happen here — when cognition and stability are at their best. The patient who has a detailed crisis advance directive in year 2 is in a completely different position from the patient whose first directive conversation happens in the ICU.[26]
MOS–
1 YR
1 YR
Refractory MG — Treatment Failure & Escalation
- Multiple immunosuppressive agents tried and failed. IVIG or PLEX required with increasing frequency. Steroid burden accumulating — Cushingoid features, osteoporosis, cataracts, diabetes.
- Recurrent crises with diminishing remissions. Biologic therapy (eculizumab, efgartigimod, rituximab) initiated if available and affordable.
- Quality of life increasingly defined by the medication schedule, infusion appointments, and anticipatory anxiety about the next crisis.
- This is the most important palliative integration window and it is almost never used. The patient receiving IVIG every 6 weeks and managing life around it deserves a frank conversation about what they are working toward.[24]
WKS–
MOS
MOS
End-Stage Refractory MG — Hospice Enrollment
- IVIG and PLEX providing shorter and shorter remissions or no meaningful remission. Crises more frequent. Functional status declining between crises.
- Bulbar weakness persistent even between crises — dysphagia requiring modified diet, dysarthria affecting communication. Respiratory reserve reduced — baseline FVC trending downward.
- Exhaustion from the disease course explicit. Hospice enrollment most appropriate at this transition.
- The advance crisis directive must be completed, specific, and posted. Pyridostigmine timing optimization. Danger list posted and communicated. Comfort kit prepared with crisis medications.[27]
DAYS–
WKS
WKS
Pre-Active Dying — Terminal Phase
- Bulbar weakness making oral intake unsafe or impossible. PEG for medications if placed; if not, subcutaneous routes for comfort medications.
- Respiratory failure progressive — may be acute (crisis) or gradual (cumulative weakness). Secretion management becomes primary concern.
- Pyridostigmine dose may need reduction if cholinergic side effects compound secretion burden. Crisis advance directive now governs all decisions.
- Family preparation for respiratory death is essential. In MG, death most commonly comes from respiratory failure or aspiration. The family must understand what this will look like and what medications are available to keep the patient comfortable.[3]
HRS–
DAYS
DAYS
Final Hours
- Respiratory effort diminishing. May see Cheyne-Stokes or irregular breathing patterns. Secretions may increase as swallowing reflex fails completely.
- Consciousness may fluctuate — MG patients can be alert even with severe respiratory compromise, then decline rapidly. This is different from other terminal trajectories.
- Morphine for dyspnea, glycopyrrolate for secretions, midazolam for respiratory distress or agitation — have all three pre-drawn and labeled at the bedside.
- The MG patient's final hours may include a characteristic pattern: periods of alertness interspersed with increasing respiratory failure. Family should be told: your person may be able to hear you even when they cannot respond. Speak to them. Hold their hand. Your presence matters.[27]
Medications to Anticipate
Symptom-targeted pharmacology for this diagnosis. What to have in the comfort kit, what to titrate first, and what the evidence supports.
MG medication management has two overriding safety obligations. First: the DANGER LIST — the following drug classes must never be prescribed to an MG patient without specialist review: aminoglycosides (gentamicin, tobramycin, neomycin), fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin), macrolides (azithromycin, erythromycin, clarithromycin), beta-blockers (propranolol, metoprolol, atenolol — systemic and eye drops), calcium channel blockers at high doses (verapamil, diltiazem), magnesium in any form (including antacids, laxatives, IV), neuromuscular blocking agents, chloroquine/hydroxychloroquine, botulinum toxin, iodinated contrast, D-penicillamine. This list must be posted in the home, in the chart, and communicated to every provider.[5]
Second: cholinergic vs myasthenic crisis distinction. Pyridostigmine overdose causes cholinergic crisis (excessive secretions, fasciculations, abdominal cramping, bradycardia) which can mimic myasthenic crisis worsening. In cholinergic crisis, pyridostigmine must be stopped. In myasthenic crisis, pyridostigmine may be appropriate. Distinguishing them requires clinical expertise. When in doubt, call the neuromuscular specialist before adjusting pyridostigmine.[37]
| Drug | Class / Target Symptom | Starting Dose | Notes / Cautions |
|---|---|---|---|
| Pyridostigmine | AChE inhibitor / Symptomatic MG | 60–90 mg PO q4–6h; time 30–45 min before meals | Foundational symptomatic treatment. Max 120 mg q4h before cholinergic risk. Liquid 60 mg/5 mL for PEG. IV: 2 mg = 60 mg oral. ⚠ Monitor for cholinergic crisis signs: excessive secretions, fasciculations, bradycardia, diarrhea.[17] |
| Prednisone | Corticosteroid / Immunosuppression | Continue current dose; taper gradually if indicated | Do not stop abruptly — adrenal crisis risk. Liquid or crushed for PEG. Monitor glucose, bone density implications. Cushingoid features expected in long-term MG patients.[15] |
| Morphine | Opioid / Dyspnea + Pain | 2.5–5 mg PO/SQ q4h PRN; ATC for persistent dyspnea | First-line for MG-related dyspnea from respiratory muscle weakness. Start low — MG patients may have increased sensitivity due to compromised respiratory reserve. Titrate to comfort. ⚠ Respiratory depression risk requires careful titration in MG.[38] |
| Glycopyrrolate | Anticholinergic / Secretions | 0.2 mg SQ q4h PRN; 0.6–1.2 mg/24h CSCI | Preferred for secretion management. ⚠ CAUTION: anticholinergics can theoretically worsen MG weakness. Use lowest effective dose. Monitor for paradoxical weakness increase. Glycopyrrolate preferred over atropine (less CNS penetration).[38] |
| Midazolam | Benzodiazepine / Respiratory distress + Terminal agitation | 2.5–5 mg SQ PRN; 10–30 mg/24h CSCI for refractory | For respiratory distress in crisis when intubation is declined. Terminal agitation. Pre-draw and label at bedside. ⚠ Respiratory depression — appropriate in comfort context when dyspnea is the dominant symptom.[38] |
| Lorazepam | Benzodiazepine / Anxiety | 0.5–1 mg PO/SL q6h PRN | For crisis cycle anxiety — the anticipatory dread of the next exacerbation. Sublingual formulation for patients with swallowing difficulty. Limit scheduled use unless anxiety is persistent and severe.[38] |
| Hyoscine butylbromide | Anticholinergic / Secretions (alternative) | 20 mg SQ q4h PRN | Alternative to glycopyrrolate if glycopyrrolate unavailable. Does not cross BBB — no CNS effects. Same caution about anticholinergic effects on MG weakness. Use only when glycopyrrolate is unavailable. |
| Ondansetron | 5-HT3 antagonist / Nausea | 4–8 mg PO/SL/SQ q8h PRN | Safe antiemetic in MG. Preferred over metoclopramide. No neuromuscular junction effects. Constipation side effect — monitor bowel function.[38] |
| Mirtazapine | Antidepressant / Depression + Insomnia + Anorexia | 7.5–15 mg PO QHS | Addresses depression, insomnia, and anorexia simultaneously. No neuromuscular junction effects. Sedation at lower doses. Safe in MG.[39] |
| Senna + Docusate | Laxative / Opioid-induced constipation | Senna 8.6–17.2 mg PO QHS; Docusate 100 mg PO BID | Start bowel regimen with first opioid dose. ⚠ Do NOT use magnesium-containing laxatives (MgCitrate, Milk of Magnesia) — magnesium is on the MG danger list. Use senna, bisacodyl, lactulose, or PEG 3350 instead.[5] |
🌿 Symptom Management Decision Tree — Myasthenia Gravis
Evidence-based · MG-specific · Hospice-adaptedSelect a symptom below to begin
What is the primary symptom to address?
🚨 Comfort Kit Must-Haves for Myasthenia Gravis
- Morphine 20 mg/mL concentrated oral solution — for dyspnea from respiratory muscle failure; 0.25–0.5 mL (5–10 mg) sublingual if unable to swallow
- Midazolam 5 mg/mL injectable — for respiratory distress crisis when intubation is declined; 2.5–5 mg SQ PRN; pre-draw and label
- Glycopyrrolate 0.2 mg/mL injectable — for secretion management as swallowing fails; 0.2 mg SQ q4h; pre-draw and label
- Lorazepam 2 mg/mL injectable or 0.5 mg sublingual tablets — for crisis anxiety and anticipatory distress
- Pyridostigmine liquid 60 mg/5 mL — for continued symptomatic treatment via PEG or measured oral dosing when tablets cannot be swallowed
- Printed danger list — posted on refrigerator, in medication box, carried by patient, filed in chart
Pre-draw and label morphine and midazolam syringes. In MG respiratory crisis, minutes matter. The family and on-call nurse need these medications ready before the crisis, not during it. Label each syringe with drug name, dose, route, and indication: "Morphine 5 mg SQ — for breathing difficulty" and "Midazolam 2.5 mg SQ — for severe breathing distress."
Clinician Pointers
High-yield clinical pearls for the hospice team. The things not in the textbook — learned at the bedside over years of clinical experience.
1
The danger list is your first clinical task at every visit
At enrollment, provide the family with a printed danger list, post it in the home, add it to the emergency information sheet, and formally communicate it to the patient's PCP, any specialist, and any urgent care or ED that might prescribe for this patient. The MG patient who receives azithromycin for a respiratory infection from a well-meaning urgent care provider has received a medication that may precipitate crisis. The danger list posted in the home and carried by the patient is the clinical intervention that prevents this. Review it at every visit — has anyone prescribed from the list since the last visit?[5]
2
Pyridostigmine timing produces immediate measurable benefit
The patient whose pyridostigmine is dosed on a fixed schedule without regard to meal timing is not receiving the full benefit of the medication. Moving the dose to 30–45 minutes before meals specifically for bulbar function during eating can meaningfully extend the period of safe oral intake. Assess the current timing at enrollment and correct it. This is a zero-cost, zero-risk intervention with immediate clinical impact. Write the meal-medication schedule on the refrigerator alongside the danger list.[17]
3
Distinguishing myasthenic crisis from cholinergic crisis is clinically crucial
Both cause weakness and respiratory distress. Myasthenic crisis: weakness without cholinergic signs — from disease exacerbation or trigger. Cholinergic crisis: from pyridostigmine overdose — produces excessive secretions, diarrhea, abdominal cramping, small pupils, bradycardia, muscle fasciculations. The wrong adjustment worsens either crisis. If in doubt, call the neuromuscular specialist before adjusting pyridostigmine. Calling for help on this specific question is clinical wisdom, not inadequacy.[37]
4
The crisis advance directive in MG must be MG-specific
Standard DNR/DNI is insufficient. The MG patient needs a directive covering: (1) whether to intubate at all for a crisis; (2) whether to attempt time-limited intubation (e.g., 72 hours for IVIG/PLEX to work, then reassess); (3) whether to pursue tracheostomy if extubation fails; (4) what comfort measures to use if intubation is declined. Facilitate this at enrollment during stability. It is the most important document in the care plan and the greatest gift to a patient whose voice may be unavailable during crisis.[26]
5
Anticholinergics for secretions require extra caution in MG
Glycopyrrolate and hyoscine butylbromide reduce secretions — essential at end of life. But anticholinergic drugs can theoretically worsen MG weakness by blocking acetylcholine. Use the lowest effective dose. Monitor for paradoxical weakness increase after anticholinergic administration. If weakness worsens, reduce anticholinergic dose and reposition for secretion drainage instead. Glycopyrrolate is preferred over atropine (less CNS penetration).[38]
6
Racial and socioeconomic disparities affect MG care access
Black patients with MG present with more severe disease, more frequent crises, and higher mortality — reflecting both phenotypic differences and systemic barriers to specialist access, IVIG availability, and insurance coverage for biologics. The hospice clinician's role: ensure every patient receives the same level of comfort-focused intervention, advocate for IVIG/PLEX access when it serves comfort goals regardless of insurance complexity, and document disparities encountered for quality improvement.[16]
7
Family exhaustion in MG is disease-specific and profound
MG families have lived with years of unpredictable crises, multiple ICU admissions, and the constant vigilance of watching for the next exacerbation. By the time of hospice enrollment, the primary caregiver has often developed their own crisis response patterns — hypervigilance, insomnia, anticipatory panic. Screen the caregiver for PTSD-like symptoms. Connect with social work. The caregiver who has been through six ICU admissions has a different grief profile than the caregiver of a patient with a newly diagnosed terminal illness.[40]
"The MG patient who looks stable when you walk in the door may not be stable when you walk out. Assess the breathing at the beginning and end of every visit. If the respiratory rate has gone up and the voice has gotten weaker during your 30-minute visit, that is not normal fatigue — that is a patient showing you what this disease does over the course of a day. Document it. Act on it. Do not wait for the crisis to declare itself."
— Waldo, NP
Psychosocial & Spiritual Care
Existential distress, depression screening, spiritual assessment, and goals-of-care communication. The symptom burden you can't see on a vitals sheet.
Psychosocial and spiritual distress in refractory MG carries a specific character that distinguishes it from most other hospice diagnoses. The patient has not experienced a single devastating diagnosis followed by decline. They have experienced years of crisis-remission cycles — each crisis bringing them to the edge, each remission giving them hope, each subsequent crisis remitting a little less completely. The exhaustion is not just physical. It is the accumulated psychological weight of living on a cliff edge for years, never knowing when the ground will give way again.[40]
Depression in refractory MG is underdiagnosed and undertreated. Studies report depression rates of 30–40% in MG patients — higher than most chronic neurological diseases. The challenge: distinguishing depression from appropriate grief about a devastating disease, and distinguishing MG fatigue from depressive fatigue. Screen every patient. PHQ-2 at enrollment. Mirtazapine is first-line in this population — addresses depression, insomnia, and anorexia simultaneously without neuromuscular junction effects.[39]
The Exhaustion of the Crisis-Remission Cycle
Recognizing Crisis Cycle Exhaustion
Grade BThe patient has lived for years with the knowledge that a bad night's sleep, an infection, a medication error, or a stressful week can send them to the ICU. The anticipatory anxiety is profound and chronic. By end-stage, many develop a specific hypervigilance — monitoring every symptom, every fluctuation, every moment of fatigue for the crisis that may be coming.
- Validate the vigilance explicitly: "You have been on alert for years. That is exhausting in a way that people who haven't lived with MG cannot understand."
- This recognition — that the vigilance itself is a burden — is often the first time anyone has named what the patient has been carrying.
The Grief of Fluctuating Illness
Grade BIn most hospice diagnoses there is a clear functional decline. In MG, the decline is not linear and the good days are genuinely good. The family whose person had a good week may question whether hospice was the right decision.
- Help frame good days as gifts within end-stage disease, not as evidence of recovery.
- The conceptual shift from "he's getting better" to "this is what end-stage MG looks like — good days and bad days, with more bad days and harder crises than before" is a clinical education task at every visit.[6]
The Decision to Stop IVIG or PLEX
For many MG patients, the regular infusion is not just a treatment — it is the ritual that represents the medical system's commitment to keeping them alive. Stopping it feels like being abandoned by medicine. The hospice clinician who frames the discontinuation explicitly as a different kind of commitment — not abandonment but a shift to the most intensive comfort care available — can transform a moment of loss into a moment of being truly seen. Say it directly: "We are not giving up on you. We are redirecting everything we have toward your comfort."[24]
Clinical Pearl
"The MG patient who says 'I'm tired of fighting' is not depressed (screen for it, but don't assume it). They are often making the most clear-eyed assessment of their situation that anyone in the room has made. They know exactly what happens in a crisis. They've been through it six times. When they say they don't want to do it again, believe them — and help them document it while they can still speak."
Spiritual Assessment & Meaning-Making
- 01Identity loss in MG is specific: The disease takes the face first (ptosis, facial weakness), then the voice (dysarthria), then the ability to eat (dysphagia). These are losses of social identity — the ability to express, to share a meal, to be recognized. Name them. They are grief points that deserve acknowledgment.[40]
- 02Legacy work is especially important: When the voice may be lost, capturing it is urgent. Audio or video recordings during periods of strength. Written letters. Life narrative through dignity therapy. Do this early in enrollment when bulbar function is best — not later when speech may be unintelligible.
- 03The guilt of "choosing to stop": In MG, unlike cancer, the patient often feels they are making a choice to stop fighting rather than losing a battle. This reframing from "disease took my options" to "I chose to stop pursuing options" can cause profound guilt. The chaplain and social worker can help reframe: "You have fought longer and harder than most people can imagine. This is not giving up. This is choosing peace."
- 04Unfinished business — the urgency of fluctuation: In a stable disease trajectory, there is often a predictable window for final conversations. In MG, that window can close without warning. Encourage families to have important conversations during good periods. Don't wait for the "right time" — in MG, the right time is whenever the patient is having a good day.[26]
"I had an MG patient whose wife kept saying, 'But he was fine on Tuesday.' And he was. Tuesday was a good day. But the trend over six months was unmistakable — each good day a little less good, each crisis a little deeper. My job was not to take Tuesday away from her. My job was to help her hold Tuesday and the truth at the same time. That's what MG hospice care is: holding two things that feel impossible together."
— Waldo, NP · Terminal2
Family Guide
Plain language for families. Share, print, or read aloud at the bedside.
Myasthenia gravis is a disease of the connections between nerves and muscles. Your loved one's immune system has been attacking those connections, making their muscles weak — especially the muscles that control breathing, swallowing, speaking, and eye movement. This is not a disease they caused. It is not something they could have prevented. What makes MG unique is its fluctuation — symptoms change hour to hour and day to day. Good days are real. Bad days are real. Both are part of this disease, and both will continue. Your most important jobs now are to know the medication danger list, time the Mestinon before meals, and know when to call the nurse.
Próximamente en español. — Coming soon in Spanish.
What You May See
- Weakness that comes and goes: Your person may be stronger in the morning and weaker by evening. Strength fades with use and improves with rest. Build the day's activities around the morning and rest periods.
- Worsening speech or swallowing toward the end of meals: This is bulbar weakness — the muscles tire during eating. Smaller, more frequent meals. Rest between bites. Give the Mestinon 30–45 minutes before the meal — this helps significantly.
- Drooping eyelids, double vision, or facial weakness: These fluctuate and do not require emergency action unless accompanied by breathing difficulty or worsening swallowing.
- Breathing that seems more difficult or faster: This is serious. Call the nurse immediately. Do not wait to see if it improves. Early respiratory change may allow home management rather than crisis.
- Good days and bad days without a consistent pattern: This is MG. A good day does not mean recovery. A bad day does not always mean crisis. Track the pattern and report it — the nurse uses the trend to assess the overall trajectory.
How You Can Help
- Know the danger list completely: It is posted on the refrigerator and on a card. Before giving any medication — including OTC products, supplements, or antibiotics from any provider — check the list. If something is on the list, call the nurse before giving it. This single step prevents the most dangerous avoidable crises.
- Give Mestinon 30–45 minutes before meals: Time meals around the medication. Do not give Mestinon with the meal. The timing is clinical, not flexible. Write the schedule on the refrigerator.
- Know the crisis advance directive: It is posted in the home. It tells you exactly what your person has said they want if a breathing crisis occurs. Read it now, not during the crisis. If you have questions, ask the nurse to review it with you.
- Keep the environment cool: Heat worsens MG. Keep the room at 68–72°F. Avoid hot baths. A fan directed at the face helps with both comfort and breathing.
- Take care of yourself: You have been doing this for years. The constant vigilance — watching for the next crisis, managing the medication schedule, coordinating the infusions — is exhausting. Call us when you need support. You are part of the care team, and the team takes care of its own.
📞 Call the nurse immediately if you see:
Any new breathing difficulty — faster breathing, shorter sentences, visible effort, or the patient saying "I can't breathe" or "it's harder to breathe." Sudden worsening of swallowing — choking on liquids that were previously tolerated, inability to swallow medications. Any medication from the danger list given by any provider — call immediately even if no symptoms yet. Fever or signs of infection — infection is the most common trigger for MG crisis; any fever in MG requires urgent assessment. New double vision combined with worsening weakness — this pattern suggests an exacerbation in progress. The patient cannot speak clearly enough to be understood — worsening dysarthria combined with other symptoms signals escalation.
🙏 You have been your person's first responder, medication manager, and advocate through years of this disease. That matters more than any treatment we can offer. Research consistently shows that patients with engaged, informed family caregivers have fewer crises, fewer hospitalizations, and better quality of life. You are not just watching — you are making a measurable clinical difference every day. When this feels impossible, remember: your presence at the bedside is the most powerful comfort intervention we know.
Waldo's Top 10 Tips
Clinical field wisdom from 12+ years at the bedside. The things you learn after doing this long enough. Not guidelines — real.
- 01The danger list is your first clinical task at every MG visit. Before you assess symptoms, before you review medications, verify that the danger list is posted and current, that the family has checked every new medication against it, and that no provider has prescribed from the list since the last visit. The MG patient who received azithromycin for a sinus infection and ended up in the ICU had a preventable crisis. The hospice nurse who catches it before it is given has done more than any medication adjustment. Print it. Post it. Carry it. Check it. Every visit.
- 02Timing pyridostigmine 30–45 minutes before meals is a clinical intervention that produces immediate, measurable benefit in bulbar MG. This seems like a small thing. It is not. The patient who takes Mestinon with meals is getting maximum benefit after the meal rather than during it. Moving the dose one step earlier can meaningfully extend the period of safe oral eating. I have seen patients gain weeks of oral intake from this single change. Assess the timing at enrollment and correct it if wrong. Write the schedule on the refrigerator in permanent marker.
- 03The distinction between myasthenic crisis and cholinergic crisis is the clinical competency that defines MG hospice. Both cause weakness and respiratory distress. One requires more treatment, one requires stopping treatment. Look for the cholinergic signs: excessive secretions, diarrhea, fasciculations, small pupils, bradycardia. If they are there, the pyridostigmine dose is too high. If they are not, the disease is worsening. If you are not confident in the distinction, call the neuromuscular specialist before adjusting pyridostigmine. Calling for help on this specific question is clinical wisdom, not inadequacy.
- 04The crisis advance directive in MG must be specific and must be created during stability — not generic DNR/DNI boilerplate but a detailed document specifying what the patient wants for each crisis scenario. Whether to intubate. Whether to attempt time-limited intubation for IVIG/PLEX. Whether to pursue tracheostomy. What comfort measures to use if intubation is declined. Facilitate this at enrollment. It is the most important document in the care plan and the greatest gift you can give a patient whose voice may be unavailable during the crisis that defines their final chapter.
- 05Magnesium in any form can precipitate myasthenic crisis. This is not theoretical — this is well-documented and lethal. The MG patient whose family gives them Milk of Magnesia for constipation has received a drug from the danger list. The MG patient who is given IV magnesium for hypomagnesemia in the ER has received a drug that can stop their breathing. Every laxative, every antacid, every electrolyte replacement must be checked for magnesium content. Replace with senna, bisacodyl, lactulose, or PEG 3350 for constipation. Use calcium carbonate for heartburn. This is the danger list item that catches everyone off guard.
- 06Anticholinergics for secretion management in MG are a clinical tightrope. Glycopyrrolate and hyoscine reduce secretions — essential at end of life. But anticholinergics can theoretically worsen MG weakness by blocking acetylcholine at the neuromuscular junction. Use the lowest effective dose. Start low. Monitor for paradoxical weakness. If secretions are the dominant symptom and weakness is already maximal, the tradeoff favors secretion control. But know you are making a tradeoff, and document it.
- 07Good days in MG are not evidence of recovery, and families need to hear this gently, repeatedly, and without taking away the joy of the good day. I say it this way: "Today is a gift. Enjoy it completely. It does not change what this disease is doing over time, but it does not need to. Today is today." The family that understands this — that can hold a good Tuesday and a terrible trajectory at the same time — is a family that will not be blindsided by the next crisis. Help them hold both.
- 08Black patients with MG experience more severe disease, more frequent crises, and higher mortality. Some of this is biological phenotype. Much of it is structural — delayed specialist access, insurance barriers to IVIG, geographic distance from neuromuscular centers, and the historical mistrust of medical systems that delays care-seeking. The hospice clinician's job is not just to acknowledge this but to actively compensate: advocate harder for IVIG access when it serves comfort goals, ensure medication supply is uninterrupted, and never assume that a patient's prior care reflects the care they deserved.
- 09The MG caregiver is not a new caregiver. They have been doing this for years — maybe decades. They know what a crisis looks like. They know the medication schedule better than most pharmacists. They have been to the ICU six times. By the time they get to hospice, many of them are running on fumes held together by adrenaline and guilt. Screen the caregiver. Ask directly: "How are you sleeping? When did you last leave the house? Are you eating?" The caregiver who has been in crisis mode for five years does not automatically shift to hospice mode. They need permission to rest. Give it explicitly.
- 10MG patients often die from what their disease does to breathing and swallowing — respiratory failure and aspiration. It is not a dramatic death in most cases. It is a gradual quieting. The breathing gets a little shallower. The pauses get a little longer. The secretions that they can no longer clear accumulate softly. If you have done your job — morphine for dyspnea, glycopyrrolate for secretions, midazolam if needed, family at the bedside, advance directive honored — then the final hours can be peaceful. That is what this work is for. Not to cure what cannot be cured, but to ensure that the ending honors the fight that came before it.
— Waldo, NP
References
Peer-reviewed citations. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.
1
Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016;375(26):2570-2581.
2
Mantegazza R, Antozzi C. When Myasthenia Gravis Is Deemed Refractory: Clinical Signposts and Treatment Strategies. Ther Adv Neurol Disord. 2018;11:1756285617749134.
3
Wendell LC, Levine JM. Myasthenic Crisis. Neurohospitalist. 2011;1(1):16-22.
4
Marx A, Pfister F, Schalke B, Saruhan-Direskeneli G, Melms A, Ströbel P. The Different Roles of the Thymus in the Pathogenesis of the Various Myasthenia Gravis Subtypes. Autoimmun Rev. 2013;12(9):875-884.
5
Nicolle MW. Myasthenia Gravis and Lambert-Eaton Syndrome: Diagnosis and Treatment. Continuum (Minneap Minn). 2016;22(6):1978-2005.
6
Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Corticosteroids for Myasthenia Gravis. Cochrane Database Syst Rev. 2005;(2):CD002828.
7
Evoli A, Tonali PA, Padua L, et al. Clinical Correlates with Anti-MuSK Antibodies in Generalized Seronegative Myasthenia Gravis. Brain. 2003;126(10):2304-2311.
8
Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to Low-Density Lipoprotein Receptor-Related Protein 4 in Myasthenia Gravis. Ann Neurol. 2011;69(2):418-422.
9
Oh SJ, Kim DE, Kuruoglu R, Bradley RJ, Dwyer D. Diagnostic Sensitivity of the Laboratory Tests in Myasthenia Gravis. Muscle Nerve. 1992;15(6):720-724.
10
Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia Gravis: Recommendations for Clinical Research Standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55(1):16-23.
11
Rabinstein AA, Mueller-Kronast N. Risk of Extubation Failure in Patients with Myasthenic Crisis. Neurocrit Care. 2005;3(3):213-215.
12
Gajdos P, Chevret S, Toyka KV. Intravenous Immunoglobulin for Myasthenia Gravis. Cochrane Database Syst Rev. 2012;12:CD002277.
13
Abel M, Eisenkraft JB. Anesthetic Implications of Myasthenia Gravis. Mt Sinai J Med. 2002;69(1-2):31-37.
14
Nacu A, Andersen JB, Lisber M, Owe JF, Gilhus NE. Complicating Autoimmune Diseases in Myasthenia Gravis: A Review. Autoimmunity. 2015;48(6):362-368.
15
Sanders DB, Wolfe GI, Benatar M, et al. International Consensus Guidance for Management of Myasthenia Gravis: Executive Summary. Neurology. 2016;87(4):419-425.
16
Hehir MK, Li Y, Jaweed S, et al. Myasthenia Gravis in African Americans: Characteristics and Treatment Patterns. J Neurol Sci. 2018;396:209-215.
17
Maggi L, Mantegazza R. Treatment of Myasthenia Gravis: Focus on Pyridostigmine. Clin Drug Investig. 2011;31(10):691-701.
18
Hart IK, Sathasivam S, Sharshar T. Immunosuppressive Agents for Myasthenia Gravis. Cochrane Database Syst Rev. 2007;(4):CD005224.
19
Díaz-Manera J, Martínez-Hernández E, Querol L, et al. Long-Lasting Treatment Effect of Rituximab in MuSK Myasthenia. Neurology. 2012;78(3):189-193.
20
Gajdos P, Chevret S, Toyka K. Plasma Exchange for Myasthenia Gravis. Cochrane Database Syst Rev. 2002;(4):CD002275.
21
Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and Efficacy of Eculizumab in Anti-Acetylcholine Receptor Antibody-Positive Refractory Generalised Myasthenia Gravis (REGAIN): A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study. Lancet Neurol. 2017;16(12):976-986.
22
Howard JF Jr, Bril V, Vu T, et al. Safety, Efficacy, and Tolerability of Efgartigimod in Patients with Generalised Myasthenia Gravis (ADAPT): A Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial. Lancet Neurol. 2021;20(7):526-536.
23
Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized Trial of Thymectomy in Myasthenia Gravis. N Engl J Med. 2016;375(6):511-522.
24
Amato AA, Russell JA. Neuromuscular Disorders, Chapter on Palliative Care Considerations. McGraw-Hill. 2016; 2nd ed.
25
Grob D, Brunner N, Namba T, Pagala M. Lifetime Course of Myasthenia Gravis. Muscle Nerve. 2008;37(2):141-149.
26
Andersen PM, Abrahams S, Borasio GD, et al. EFNS Guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) — Revised Report of an EFNS Task Force. Eur J Neurol. 2012;19(3):360-375.
27
Rabinstein AA, Wijdicks EFM. BiPAP in Acute Respiratory Failure Due to Myasthenic Crisis May Prevent Intubation. Neurology. 2002;59(10):1647-1649.
28
Fregonezi GA, Resqueti VR, Guell R, Pradas J, Casan P. Effects of 8-Week, Interval-Based Inspiratory Muscle Training and Breathing Retraining in Patients with Generalized Myasthenia Gravis. Chest. 2005;128(3):1524-1530.
29
Twork S, Wiesmeth S, Klewer J, Pohlau D, Kugler J. Quality of Life and Life Circumstances in German Myasthenia Gravis Patients. Health Qual Life Outcomes. 2010;8:129.
30
Askmark H, Haggård L, Nygren I, Punga AR. Vitamin D Deficiency in Patients with Myasthenia Gravis and Improvement of Fatigue after Supplementation of Vitamin D3: A Pilot Study. Eur J Neurol. 2012;19(12):1554-1560.
31
Coenzyme Q10 in Neuromuscular Disease. Expert Panel Review. J Clin Neuromuscul Dis. 2005;6(3):129-146.
32
Forrest CM, Mackay GM, Stoy N, et al. Inflammatory Status and Kynurenine Metabolism in Rheumatoid Arthritis Treated with Melatonin. Br J Clin Pharmacol. 2007;64(4):517-526.
33
Calder PC. Omega-3 Fatty Acids and Inflammatory Processes: From Molecules to Man. Biochem Soc Trans. 2017;45(5):1105-1115.
34
Rinaldi E, Consonni A, Guidesi E, Ber EC, Mantegazza R, Bhlin EP. Gut Microbiota and Probiotics: Novel Immune System Modulators in Myasthenia Gravis? Ann N Y Acad Sci. 2018;1413(1):49-58.
35
Bashuk RG, Krendel DA. Myasthenia Gravis Presenting as Weakness After Magnesium Administration. Muscle Nerve. 1990;13(8):708-712.
36
Jani-Acsadi A, Lisak RP. Myasthenic Crisis: Guidelines for Prevention and Treatment. J Neurol Sci. 2007;261(1-2):127-133.
37
Thomas CE, Mayer SA, Gungor Y, et al. Myasthenic Crisis: Clinical Features, Mortality, Complications, and Risk Factors for Prolonged Intubation. Neurology. 1997;48(5):1253-1260.
38
Twycross R, Wilcock A, Howard P. Palliative Care Formulary. 7th Edition. Pharmaceutical Press. 2020.
39
Paul RH, Nash JM, Cohen RA, Gilchrist JM, Goldstein JM. Quality of Life and Well-Being of Patients with Myasthenia Gravis. Muscle Nerve. 2001;24(1):25-31.
40
Basta IZ, Pekmezović TD, Perić SZ, et al. Assessment of Health-Related Quality of Life in Patients with Myasthenia Gravis in Belgrade (Serbia). Neurol Sci. 2012;33(6):1375-1381.
41
Skeie GO, Apostolski S, Evoli A, et al. Guidelines for Treatment of Autoimmune Neuromuscular Transmission Disorders. Eur J Neurol. 2010;17(7):893-902.
42
Benatar M. A Systematic Review of Diagnostic Studies in Myasthenia Gravis. Neuromuscul Disord. 2006;16(7):459-467.
43
Meriggioli MN, Sanders DB. Autoimmune Myasthenia Gravis: Emerging Clinical and Biological Heterogeneity. Lancet Neurol. 2009;8(5):475-490.
44
Barohn RJ. Standards of Measurement in Myasthenia Gravis. Ann N Y Acad Sci. 2003;998:432-439.
45
Silvestri NJ, Wolfe GI. Treatment-Refractory Myasthenia Gravis. J Clin Neuromuscul Dis. 2014;15(4):167-178.
46
Gilhus NE, Verschuuren JJ. Myasthenia Gravis: Subgroup Classification and Therapeutic Strategies. Lancet Neurol. 2015;14(10):1023-1036.
47
Berrih-Aknin S, Le Panse R. Myasthenia Gravis: A Comprehensive Review of Immune Dysregulation and Etiological Mechanisms. J Autoimmun. 2014;52:90-100.
48
Spillane J, Higham E, Kullmann DM. Myasthenia Gravis. BMJ. 2012;345:e8497.
terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. All PMIDs hyperlinked. © Terminal2 | terminal2.care
Private Notes
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.